SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
LTGO

Latigo Biotherapeutics, Inc. (NASDAQ:LTGO)

US · Delayed Price · Currency is USD
Healthcare · Medical - Pharmaceuticals
$13.00-$0.24 (-1.81%)
 
Market cap
$782M
Insider Score
Health Score
Listed since
Aug 7, 2026
Market Cap$781.99M-28.8%
Revenue (ttm)$0
Net Income-$107.29M
EPS-$2.35
Shares Out66.30M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume267,166
Open$13.22
Previous Close$13.24
Day's Range$11.91 - $13.35
52-Week Range$10.24 - $25.93
Betan/a
Analystsn/a
Price Target$52.25(+301.92%)
Earnings DateMar 3, 2027

About LTGO

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.

Address
1300 Rancho Conejo Boulevard, Suite 305, Thousand Oak, CA, 91320, US
Market Cap
782 million
Employees
66
Industrial Classification
Medical - Pharmaceuticals

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$5.04M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

When insiders bought and sold

1 year · open-market trades only
Closing Price Purchase Sale
$11.59$18.92$26.25SepNov
Financial Health Score
Sound
From LTGO’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-1.81%
5 Days
+0.08%
1 Month
-21.54%
6 Months
-28.77%
1 Year
-28.77%

$LTGO stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in LTGO holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by LTGO's directors and management

Net Shares Purchased by Insiders−300k−150k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

LTGO Estimated quarterly lobbying spending

Source: U.S. Senate LDA

LTGO Revenue by Segment

$10.09MTotal
Other clinical and non-clinical programs$5.15M51.01%
Direct Program Costs Onzotrigine$4.94M48.99%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New LTGO patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to LTGO from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in LTGO

VTIVanguard Morningstar Total Stock Market ETF$6.92M
VXFVanguard Extended Market ETF$3.03M
SCHASchwab U.S. Small-Cap ETF$1.28M
SCHBSchwab U.S. Broad Market ETF$153.37K
VTWOVanguard Russell 2000 ETF$110.41K
VTWGVanguard Russell 2000 Growth ETF$11.02K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from LTGO’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
17.8
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
2
Sells
0
Buy Value
$5.04M
Distinct Buyers
2

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.